December 12, 2019 09:30 AM Eastern Standard Time
CAMBRIDGE, Mass. (BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc., today announced the appointment of Debra Canner as the company’s first Global Head of Human Resources. Deb will serve on Amylyx’ Executive Team, overseeing the company’s human resource efforts, including talent management, organizational leadership, culture and corporate responsibility.
Throughout her distinguished career as a human resources leader, including chief human resources officer experience at three preeminent life science and technology organizations, Deb brings a strategic yet practical approach to her work.Deb will play a large role in shaping and fostering a culture focused on attracting, retaining and developing bold, collaborative talent that aims to improve the lives those of suffering from disease.
“We’re thrilled Deb has joined us to continue building a strong core team that is eager to dedicate themselves to changing patients’ lives,” said Joshua Cohen, CEO, Chairman, and Co-Founder of Amylyx. “Deb’s tremendous experience in building and scaling companies will add great value to Amylyx and we look forward to her leadership in ensuring our culture and key growth initiatives are aligned.”
“Becoming part of the Amylyx team at this central moment in time is tremendously exciting. We have an opportunity to bring together a team dedicated to fearless innovation and that believes we can be better together to achieve our goal of helping patients.”
Prior to her CHRO roles at Akamai Technologies, Joslin Diabetes Center and Haemonetics Corporation, Deb was part of Genzyme, now a fully owned subsidiary of Sanofi, and rose to become the number two HR leader there during a period of significant growth. Since 2013, Deb has been a human resources consultant to leaders of public and private small and emerging growth life science companies with a focus on HR leadership across all areas of Human Resources. Past clients include: Gen9 Bio, CeQur, Joslin Diabetes Center, Juniper Pharmaceuticals, Navitor Pharmaceuticals, and CANbridge Pharmaceuticals.
Deb received a B.A. from the University of Massachusetts, Amherst. She holds certification in executive leadership development from the Center for Creative Leadership.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.